LGND
Ligand Pharmaceuticals (LGND) Stock Analysis
Research Ligand Pharmaceuticals (LGND) with company financials, earnings context, valuation indicators, risk analysis and related market news.
Research record updated: . Individual measures may refer to different reporting periods.
- Ticker
- LGND
- Company
- Ligand Pharmaceuticals
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $5.95B
- Financial data source
- SEC company filings + FMP cash flow statements + FMP balance sheet + income statements + StockAnalysis complete statements
- Annual revenue (reporting year not supplied)
- $268.09M
- Annual net income (reporting year not supplied)
- $124.45M
- Annual free cash flow (reporting year not supplied)
- $48.91M
- Trailing revenue
- $290.54M
- Trailing net income
- $197.22M
- Total assets
- $1.56B
- Total liabilities
- $543.43M
Ligand Pharmaceuticals (LGND) Stock Analysis research
Review the available company profile, financial history, valuation context and investor signals for Ligand Pharmaceuticals. Compare the reported operating results with the valuation and risk measures below.
The figures are cached research data and can change after new filings, earnings reports or market updates. Verify material facts with primary company disclosures before making an investment decision.